Abstract

The clinical field of rheumatology utilizes numerous medications which are either structurally derived from antibiotic compounds or are actually originally track - record proven anti - infective agents adapted for use in this field. Though in many cases, exemplified by rheumatoid arthritis, a presumed infectious etiology brought about the introduction of these drugs into rheumatology, subsequent research has often failed to demonstrate an infectious agent; nevertheless such originally anti - infectious agents as hydroxychloroquine and sulfasalazine have gained a place in the rheumatologic armamentarium. This sequence of events implies that in many cases anti - infective agents posses anti - inflammatory or immuno - modulatory qualities not directly linked to their potential capacity to kill foreign pathogens. More recently agents such as cyclosporine and tacrolimus, both of antibiotic structure, have been developed specifically for their immuno - modulatory effects. This review covers the main events in the development of anti - infective agents for rheumatology and attempts to clarify the often enigmatic relationship between these two seemingly unrelated fields. Keywords: Rheumatology, sulfasalazine, hydroxychloroquine, minocycline, tetracylines, cyclosporine, tacrolimus, rheumatoid arthritis, systemic lupus erythematosus

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.